<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Hansa Biopharma interim report January-March 2024]]></title><description><![CDATA[<p dir="auto">Hansa Biopharma interim report January-March 2024</p>
<p dir="auto"><div class="card col-md-9 col-lg-6 position-relative link-preview p-0">



<a href="https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-interim-report-january-march-2024/" title="Hansa Biopharma interim report January-March 2024 | Hansa Biopharma">
<img src="https://www.hansabiopharma.com/images/cc2675d4-702d-4061-a6b9-32744d01d973/sp/hansa_color_highres.png" class="card-img-top not-responsive" style="max-height: 15rem;" alt="Link Preview Image" onerror="this.parentElement.remove()" />
</a>



<div class="card-body">
<h5 class="card-title">
<a class="text-decoration-none" href="https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-interim-report-january-march-2024/">
Hansa Biopharma interim report January-March 2024 | Hansa Biopharma
</a>
</h5>
<p class="card-text line-clamp-3"></p>
</div>
<a href="https://www.hansabiopharma.com/media/press-releases/2024/hansa-biopharma-interim-report-january-march-2024/" class="card-footer text-body-secondary small d-flex gap-2 align-items-center lh-2">



<img src="https://www.hansabiopharma.com/favicons/favicon-32x32.png" alt="favicon" class="not-responsive overflow-hiddden" style="max-width: 21px; max-height: 21px;" onerror="this.remove()"/>









<p class="d-inline-block text-truncate mb-0"> <span class="text-secondary">(www.hansabiopharma.com)</span></p>
</a>
</div></p>
<p dir="auto">• Strong sales performance and solid momentum with the Phase 3 trial in anti-GBM disease<br />
• Cash runway extended into 2026<br />
• Evan Ballantyne joins Hansa Biopharma as Chief Financial Office</p>
]]></description><link>https://dev.proinvestor.com/forum/topic/446363/hansa-biopharma-interim-report-january-march-2024</link><generator>RSS for Node</generator><lastBuildDate>Fri, 19 Jun 2026 10:05:04 GMT</lastBuildDate><atom:link href="https://dev.proinvestor.com/forum/topic/446363.rss" rel="self" type="application/rss+xml"/><pubDate>Thu, 18 Apr 2024 03:07:45 GMT</pubDate><ttl>60</ttl><item><title><![CDATA[Reply to Hansa Biopharma interim report January-March 2024 on Fri, 19 Apr 2024 06:32:08 GMT]]></title><description><![CDATA[<p dir="auto">Nu er der rigtig mange insidere, der har aktier og har haft det gennem mange år. Der er kun solgt 2591 aktier af en insider de sidste 5 år. Jeg er godt tilfreds med, at kursen finder et naturligt leje, og det sker den dag shorterne dækker ind, formodentligt sker det snart.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/9488267</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/9488267</guid><dc:creator><![CDATA[focus]]></dc:creator><pubDate>Fri, 19 Apr 2024 06:32:08 GMT</pubDate></item><item><title><![CDATA[Reply to Hansa Biopharma interim report January-March 2024 on Thu, 18 Apr 2024 11:59:09 GMT]]></title><description><![CDATA[<p dir="auto">Med udviklingen i salget og med ny kapital har shorterne ikke meget, at "hænge deres hat på". Kursmålene ligger jo også mange gange over dagens kurs. Shorterne har travlt lige nu, for kursen skal nord på.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/9488263</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/9488263</guid><dc:creator><![CDATA[focus]]></dc:creator><pubDate>Thu, 18 Apr 2024 11:59:09 GMT</pubDate></item><item><title><![CDATA[Reply to Hansa Biopharma interim report January-March 2024 on Thu, 18 Apr 2024 11:36:37 GMT]]></title><description><![CDATA[<p dir="auto">ja men det kommer den ikke før ledelsen for alvor selv køber sig ind i casen det vil være det signal der skal til for at shorterne stempler ud og markedet får troen på firmaet tilbage</p>
]]></description><link>https://dev.proinvestor.com/forum/post/9488275</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/9488275</guid><dc:creator><![CDATA[LP90]]></dc:creator><pubDate>Thu, 18 Apr 2024 11:36:37 GMT</pubDate></item><item><title><![CDATA[Reply to Hansa Biopharma interim report January-March 2024 on Thu, 18 Apr 2024 07:15:48 GMT]]></title><description><![CDATA[<p dir="auto">Shorterne kan ikke finde noget at støtte sig til, kursen skal op.</p>
]]></description><link>https://dev.proinvestor.com/forum/post/9488265</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/9488265</guid><dc:creator><![CDATA[focus]]></dc:creator><pubDate>Thu, 18 Apr 2024 07:15:48 GMT</pubDate></item><item><title><![CDATA[Reply to Hansa Biopharma interim report January-March 2024 on Thu, 18 Apr 2024 03:12:40 GMT]]></title><description><![CDATA[<p dir="auto">Hansa Biopharma will host a telephone conference today Thursday, April 18, 2024, 14:00 CET / 8:00am EST.</p>
<p dir="auto">The webcast will be available on <a href="https://hansabiopharma.eventcdn.net/events/interim-report-january-march-2024" rel="nofollow ugc">https://hansabiopharma.eventcdn.net/events/interim-report-january-march-2024</a></p>
]]></description><link>https://dev.proinvestor.com/forum/post/9488274</link><guid isPermaLink="true">https://dev.proinvestor.com/forum/post/9488274</guid><dc:creator><![CDATA[exitnu]]></dc:creator><pubDate>Thu, 18 Apr 2024 03:12:40 GMT</pubDate></item></channel></rss>